Oppenheimer's Jay Olson reiterated a 'Buy' rating on shares of Intec Pharma Ltd. (NASDAQ:NTEC) today alongside a price target of $15.00 per share. With an analyst average price target of $12.25 per share, Olson's price target is the highest out of the analysts we track that cover Intec.
According to TheFly.com, "Olson is "incrementally more optimistic" in his outlook for Intec Pharma after meeting with management. The analyst is "encouraged" by new CEO Jeff Meckler's vision for the Accordion Pill as a platform to unlock significant value for shareholders beyond the current opportunity in Parkinson's disease."
Be sure to subscribe to one or more of our free e-mail newsletters so you never miss an important marijuana stock update. Also, don't forget to connect with The Daily Marijuana Observer on social media via Facebook, Twitter, StockTwits, YouTube, and Instagram.